Abiopharma

🔍 Cline Christopher R. (Executive)

Company: Travere Therapeutics, Inc. (TVTX)

Report Date: 2025-09-03

Detailed Transactions and Holdings:

• Sold 454 shares of Common Stock at $18.2 per share (Direct)
  Date: 2025-09-03 | Code: S | equity_swap_involved: 0 | shares_owned_after: 92,202.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 119 shares of Common Stock at $19.71 per share (Direct)
  Date: 2025-09-04 | Code: S | equity_swap_involved: 0 | shares_owned_after: 92,083.00 | transaction_form_type: 4 | Footnotes: F2

Footnotes:

• F1: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.
• F2: This sale was made pursuant to a written plan adopted on May 28, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.